| Andrea S Thornton, MD | |
|
1050 Wellington, Grand Junction, CO 81501 | |
| (970) 298-5864 | |
| (970) 298-5888 |
| Full Name | Andrea S Thornton |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 31 Years |
| Location | 1050 Wellington, Grand Junction, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629178512 | NPI | - | NPPES |
| 116274800 | Medicaid | WY | |
| 82923531 | Medicaid | CO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 6272A (Wyoming) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 49523 (Colorado) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Marys Medical Center | Grand junction, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Grand Junction Llc | 3779707856 | 207 |
News Archive
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
Two Texas-based nonprofits, Candlelighters of El Paso and the Light and Salt Association, have been named the recipients of the American Society for Radiation Oncology2018 Survivor Circle grants. Each organization will receive a $10,000 grant to aid their cancer support programs and will be recognized at an award ceremony on October 23 during ASTRO's 60th Annual Meeting in San Antonio.
ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.
ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.
Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year.
› Verified 7 days ago
| Entity Name | St Marys Hospital And Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275714081 PECOS PAC ID: 1557267069 Enrollment ID: O20031218000149 |
News Archive
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
Two Texas-based nonprofits, Candlelighters of El Paso and the Light and Salt Association, have been named the recipients of the American Society for Radiation Oncology2018 Survivor Circle grants. Each organization will receive a $10,000 grant to aid their cancer support programs and will be recognized at an award ceremony on October 23 during ASTRO's 60th Annual Meeting in San Antonio.
ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.
ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.
Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year.
› Verified 7 days ago
| Entity Name | Scl Health Medical Group - Grand Junction Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356765556 PECOS PAC ID: 3779707856 Enrollment ID: O20140611000363 |
News Archive
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
Two Texas-based nonprofits, Candlelighters of El Paso and the Light and Salt Association, have been named the recipients of the American Society for Radiation Oncology2018 Survivor Circle grants. Each organization will receive a $10,000 grant to aid their cancer support programs and will be recognized at an award ceremony on October 23 during ASTRO's 60th Annual Meeting in San Antonio.
ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.
ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.
Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea S Thornton, MD 1050 Wellington, Grand Junction, CO 81501 Ph: (970) 298-5864 | Andrea S Thornton, MD 1050 Wellington, Grand Junction, CO 81501 Ph: (970) 298-5864 |
News Archive
Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded $946,000 in funding by U.S.-based PATH pursuant to a research collaboration agreement. Medicago and PATH will work together on a broad coverage influenza vaccine based on Medicago's proprietary plant-based Virus-Like Particle (VLP) technologies for the developing world.
Two Texas-based nonprofits, Candlelighters of El Paso and the Light and Salt Association, have been named the recipients of the American Society for Radiation Oncology2018 Survivor Circle grants. Each organization will receive a $10,000 grant to aid their cancer support programs and will be recognized at an award ceremony on October 23 during ASTRO's 60th Annual Meeting in San Antonio.
ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.
ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.
Tuberculosis (TB) is a major killer, causing up to two million deaths worldwide every year.
› Verified 7 days ago
Dr. Ellen Ablog Dy, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1035 Wellington Ave, Grand Junction, CO 81501 Phone: 970-242-6600 Fax: 970-241-8443 | |
James W Thompson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1050 Wellington Ave, Grand Junction, CO 81501 Phone: 970-298-5864 Fax: 970-298-5888 | |
Gary Lee Snyder, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 425 Patterson Rd, Ste 605, Grand Junction, CO 81506 Phone: 970-244-2482 Fax: 970-255-1701 | |
Dr. Brent James Prosser, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1035 Wellington Ave, Grand Junction, CO 81501 Phone: 970-242-6600 Fax: 970-241-8443 | |
Dr. David Russell Scott, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 1120 Wellington Ave, Grand Junction, CO 81501 Phone: 970-241-0170 | |
Mitchell Gershten, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2635 N 7th St, Suite 4205, Grand Junction, CO 81501 Phone: 970-298-1995 Fax: 970-298-1992 | |
David Johansen, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 607 28 1/4 Rd, Grand Junction, CO 81506 Phone: 970-243-3300 Fax: 970-243-4464 |